Finch Therapeutics Group, Inc. (FNCH) has 11 open-market insider trades by 7 insiders since 2021. The most active filer is Jeffery A. Smisek, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Nicholas Haft | Dir | — | 2 | $15.6M | 2021-12-20 |
| Crestovo Investor LLC | Dir10% Owner | — | 1 | $12.5M | 2021-03-23 |
| Domenic J. Ferrante | Dir | — | 1 | $1.7M | 2021-03-23 |
| Jeffery A. Smisek | Dir | — | 3 | $1.5M | 2024-06-07 |
| Marc Blaustein | COO | — | 2 | $7K | 2023-02-21 |
| Joseph Vittiglio | Chief Business & Legal Officer | — | 1 | $5K | 2022-10-21 |
| Susan E. Graf | Dir | — | 1 | $1K | 2023-06-09 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Jeffery A. Smisek | Director | Sell | $21K | 2024-03-28 |
| Jeffery A. Smisek | Director | Sell | $5K | 2023-11-22 |
| Susan E. Graf | Director | Buy | $1K | 2023-06-09 |
| Marc Blaustein | COO | Sell | $2K | 2023-02-21 |
| Joseph Vittiglio | Chief Business & Legal Officer | Sell | $5K | 2022-10-21 |
| Nicholas Haft | Director | Buy | $650K | 2021-12-20 |
Companies that share insiders with FNCH, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Domenic J. Ferrante | Director | Buy | $1.7M | 2021-03-23 |
| Nicholas Haft | Director | Buy | $15.0M | 2021-03-23 |
| Jeffery A. Smisek | Director | Buy | $1.5M | 2021-03-23 |
| Crestovo Investor LLC | Director & 10% Owner | Buy | $12.5M | 2021-03-23 |